Telix spotlights Phase 3 IPAX BrIGHT trial of TLX101 — Tx in recurrent glioblastoma at EANM congress
Telix flagged multiple late-stage oncology readouts slated for the Oct. 17-21 European nuclear medicine congress in Vienna. Topline Phase 3 data for Illuccix prostate cancer PET imaging in Chinese men will be presented, positioning the product for broader commercialization. Interim results will be presented for TLX597